Stock 688389 SHENZHEN LIFOTRONIC TECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shenzhen Lifotronic Technology Co., Ltd.

Equities

688389

CNE100005WZ5

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
19.1 CNY +0.84% Intraday chart for Shenzhen Lifotronic Technology Co., Ltd. +0.90% -15.15%
Feb. 22 Shenzhen Lifotronic Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Shenzhen Lifotronic Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The company appears highly valued given the size of its balance sheet.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
SHENZHEN LIFOTRONIC TECHNOLOGY CO., LTD. Stock Shenzhen Lifotronic Technology Co., Ltd.
-15.15% 1.13B -
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-3.17% 8.22B
B-
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+6.11% 5.72B
B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+31.98% 5.67B
C
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-10.03% 4.11B
C
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-59.94% 2.68B
D+
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+11.23% 2.68B - -
VITROLIFE AB Stock Vitrolife AB
-5.14% 2.37B
B-
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+18.91% 2.06B
C
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-7.56% 1.8B
D+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. 688389 Stock
  4. Ratings Shenzhen Lifotronic Technology Co., Ltd.